Lähde: Molecular Point-of-Care Testing as Part of an Integrated Approach to Achieve Earlier Diagnosis and Treatment of HIV, presented at IAS2020, M Meulbroek.
(1) WHO HIV/AIDs Key Facts updates 6th July 2020 Haettu heinäkuussa 2020 https://www.who.int/news-room/fact-sheets/detail/hiv-aids
(2) Aids.gov. Aids Signs and Symptoms. Haettu toukokuussa 2015. https://www.aids.gov/hiv-aids-basics/hiv-aids-101/signs-and- symptoms/
(3) O'Brien M, et al. Should we treat acute HIV infection? Curr HIV/AIDS Rep. 2012 Jun;9(2):101-10.
(4) Kahn JO, et al. Acute human immunodeficiency virus type 1 infection. N Engl J Med. 1998 Jul 2;339(1):33-9,9.
(5) Daar ES, et al. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med. 1991 Apr 4;324(14):961-4,6
(6)Clark SJ, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med. 1991 Apr 4;324(14):954-60.
(7) Fonner VA, Denison J, Kennedy CE, et al. Voluntary counseling and testing (VCT) for changing HIV-related risk behavior in developing countries. Cochrane Database Syst Rev 2012;9:CD001224.
(8) Steward WT, Remien RH, Higgins JA, et al. Behavior change following diagnosis with acute/early HIV infection-a move to serosorting with other HIV-infected individuals. The NIMH Multisite Acute HIV Infection Study: III. AIDS Behav 2009;13:1054-1060.
(9) Metsch LR, Pereyra M, Messinger S, et al. HIV transmission risk behaviors among HIV-infected persons who are successfully linked to care. Clin Infect Dis 2008;47:577-584.
Xpert HIV-1 Qual XC -määritys on saatavilla vain Euroopan unionissa ja CE-merkin rekisteröinnin hyväksyvissä maissa.
Muissa maissa, joissa tuotteen rekisteröinti on meneillään,
Xpert HIV-1 Qual -määritys on saatavilla.
Uuden tuotteen saatavuudesta saa lisätietoja ottamalla yhteyttä paikalliseen Cepheid-edustajaan.